Comparative Pharmacology
Head-to-head clinical analysis: AFEDITAB CR versus CARDENE SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFEDITAB CR versus CARDENE SR.
AFEDITAB CR vs CARDENE SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It produces relaxation of coronary vascular smooth muscle and dilation of coronary arteries, and also dilates peripheral arteries, reducing systemic vascular resistance and blood pressure.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
Initial: 30 mg orally twice daily (SR capsules). Titrate up to 60 mg twice daily. Usual maintenance: 30-60 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Terminal elimination half-life 8.6 hours (range 6-15 hours). Clinical context: No accumulation at steady state with TID dosing.
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
Renal: 60% (metabolites, unchanged drug <1%); Biliary/Fecal: 35%
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker